Literature DB >> 34059678

Multiomics characteristics of neurogenesis-related gene are dysregulated in tumor immune microenvironment.

Ben Wang1, Hai Mou1, Mengmeng Liu2, Zhujie Ran3, Xin Li4, Jie Li5, Yunsheng Ou6.   

Abstract

The success of immunotherapy was overshadowed by its low response rate, and the hot or cold tumor microenvironment was reported to be responsible for it. However, due to the lack of an appropriate method, it is still a huge challenge for researchers to understand the molecular differences between hot and cold tumor microenvironments. Further research is needed to gain deeper insight into the molecular characteristics of the hot/cold tumor microenvironment. A large-scale clinical cohort and single-cell RNA-seq technology were used to identify the molecular characteristics of inflamed or noninflamed tumors. With single-cell RNA sequencing technology, we provided a novel method to dissect the tumor microenvironment into a hot/cold tumor microenvironment to help us understand the molecular differences between hot and cold tumor microenvironments. Compared with cold tumors, hot tumors highly expressed B cell-related genes, such as MS4A1 and CXCR5, neurogenesis-related miRNA such as MIR650, and immune molecule-related lncRNA such as MIR155HG and LINC00426. In cold tumors, the expression of genes related to multiple biological processes, such as the neural system, was significantly upregulated, and methylome analysis indicated that the promoter methylation level of genes related to neurogenesis was significantly reduced. Finally, we investigated the pan-cancer prognostic value of the cold/hot microenvironment and performed pharmacogenomic analysis to predict potential drugs that may have the potential to convert the cold microenvironment into a hot microenvironment. Our study reveals the multiomics characteristics of cold/hot microenvironments. These molecular characteristics may contribute to the understanding of immune exclusion and the development of microenvironment-targeted therapy.

Entities:  

Year:  2021        PMID: 34059678     DOI: 10.1038/s41525-021-00202-y

Source DB:  PubMed          Journal:  NPJ Genom Med        ISSN: 2056-7944            Impact factor:   8.617


  51 in total

1.  An immune-active tumor microenvironment favors clinical response to ipilimumab.

Authors:  Rui-Ru Ji; Scott D Chasalow; Lisu Wang; Omid Hamid; Henrik Schmidt; John Cogswell; Suresh Alaparthy; David Berman; Maria Jure-Kunkel; Nathan O Siemers; Jeffrey R Jackson; Vafa Shahabi
Journal:  Cancer Immunol Immunother       Date:  2011-12-07       Impact factor: 6.968

2.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.

Authors:  Stefani Spranger; Riyue Bao; Thomas F Gajewski
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

3.  Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies.

Authors:  Nikolas G Balanis; Katherine M Sheu; Favour N Esedebe; Saahil J Patel; Bryan A Smith; Jung Wook Park; Salwan Alhani; Brigitte N Gomperts; Jiaoti Huang; Owen N Witte; Thomas G Graeber
Journal:  Cancer Cell       Date:  2019-07-08       Impact factor: 31.743

Review 4.  Understanding the tumor immune microenvironment (TIME) for effective therapy.

Authors:  Mikhail Binnewies; Edward W Roberts; Kelly Kersten; Vincent Chan; Douglas F Fearon; Miriam Merad; Lisa M Coussens; Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Catherine C Hedrick; Robert H Vonderheide; Mikael J Pittet; Rakesh K Jain; Weiping Zou; T Kevin Howcroft; Elisa C Woodhouse; Robert A Weinberg; Matthew F Krummel
Journal:  Nat Med       Date:  2018-04-23       Impact factor: 53.440

5.  Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

Authors:  Pei-Ling Chen; Whijae Roh; Alexandre Reuben; Zachary A Cooper; Christine N Spencer; Peter A Prieto; John P Miller; Roland L Bassett; Vancheswaran Gopalakrishnan; Khalida Wani; Mariana Petaccia De Macedo; Jacob L Austin-Breneman; Hong Jiang; Qing Chang; Sangeetha M Reddy; Wei-Shen Chen; Michael T Tetzlaff; Russell J Broaddus; Michael A Davies; Jeffrey E Gershenwald; Lauren Haydu; Alexander J Lazar; Sapna P Patel; Patrick Hwu; Wen-Jen Hwu; Adi Diab; Isabella C Glitza; Scott E Woodman; Luis M Vence; Ignacio I Wistuba; Rodabe N Amaria; Lawrence N Kwong; Victor Prieto; R Eric Davis; Wencai Ma; Willem W Overwijk; Arlene H Sharpe; Jianhua Hu; P Andrew Futreal; Jorge Blando; Padmanee Sharma; James P Allison; Lynda Chin; Jennifer A Wargo
Journal:  Cancer Discov       Date:  2016-06-14       Impact factor: 39.397

Review 6.  Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.

Authors:  Jérôme Galon; Daniela Bruni
Journal:  Nat Rev Drug Discov       Date:  2019-03       Impact factor: 84.694

Review 7.  Cancer immunotherapy: harnessing the immune system to battle cancer.

Authors:  Yiping Yang
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

8.  Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.

Authors:  Akihito Kawazoe; Kensei Yamaguchi; Hisateru Yasui; Yuji Negoro; Mizutomo Azuma; Kenji Amagai; Hiroki Hara; Hideo Baba; Masahiro Tsuda; Hisashi Hosaka; Hisato Kawakami; Takashi Oshima; Yasushi Omuro; Nozomu Machida; Taito Esaki; Kazuhiro Yoshida; Tomohiro Nishina; Yoshito Komatsu; Shi R Han; Shinichi Shiratori; Kohei Shitara
Journal:  Eur J Cancer       Date:  2020-03-04       Impact factor: 9.162

9.  Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.

Authors:  Dongjun Peng; Ilona Kryczek; Nisha Nagarsheth; Lili Zhao; Shuang Wei; Weimin Wang; Yuqing Sun; Ende Zhao; Linda Vatan; Wojciech Szeliga; Jan Kotarski; Rafał Tarkowski; Yali Dou; Kathleen Cho; Sharon Hensley-Alford; Adnan Munkarah; Rebecca Liu; Weiping Zou
Journal:  Nature       Date:  2015-10-26       Impact factor: 49.962

10.  Myc Cooperates with Ras by Programming Inflammation and Immune Suppression.

Authors:  Roderik M Kortlever; Nicole M Sodir; Catherine H Wilson; Deborah L Burkhart; Luca Pellegrinet; Lamorna Brown Swigart; Trevor D Littlewood; Gerard I Evan
Journal:  Cell       Date:  2017-11-30       Impact factor: 41.582

View more
  4 in total

1.  Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma Patients.

Authors:  Shenglan Huang; Jian Zhang; Xiaolan Lai; Lingling Zhuang; Jianbing Wu
Journal:  Front Mol Biosci       Date:  2021-12-24

Review 2.  Emerging Roles of the Nervous System in Gastrointestinal Cancer Development.

Authors:  Chunhua Wan; Xiaoqin Yan; Baoying Hu; Xinhua Zhang
Journal:  Cancers (Basel)       Date:  2022-07-30       Impact factor: 6.575

3.  Pan-Cancer Analysis of the Immunological Role of PDIA5: A Potential Target for Immunotherapy.

Authors:  Yu Chen; Jialin He; Rui Chen; Zeyu Wang; Ziyu Dai; Xisong Liang; Wantao Wu; Peng Luo; Jian Zhang; Yun Peng; Nan Zhang; Zaoqu Liu; Liyang Zhang; Hao Zhang; Quan Cheng
Journal:  Front Immunol       Date:  2022-08-08       Impact factor: 8.786

4.  The Association between Immune Subgroups and Gene Modules for the Clinical, Cellular, and Molecular Characteristic of Hepatocellular Carcinoma.

Authors:  Wenbiao Chen; Peng Zhu; Huixuan Xu; Xianliang Hou; Changchun Guo
Journal:  J Oncol       Date:  2022-08-31       Impact factor: 4.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.